Literature DB >> 18614781

Noninvasive ventilation in acute cardiogenic pulmonary edema.

Alasdair Gray1, Steve Goodacre, David E Newby, Moyra Masson, Fiona Sampson, Jon Nicholl.   

Abstract

BACKGROUND: Noninvasive ventilation (continuous positive airway pressure [CPAP] or noninvasive intermittent positive-pressure ventilation [NIPPV]) appears to be of benefit in the immediate treatment of patients with acute cardiogenic pulmonary edema and may reduce mortality. We conducted a study to determine whether noninvasive ventilation reduces mortality and whether there are important differences in outcome associated with the method of treatment (CPAP or NIPPV).
METHODS: In a multicenter, open, prospective, randomized, controlled trial, patients were assigned to standard oxygen therapy, CPAP (5 to 15 cm of water), or NIPPV (inspiratory pressure, 8 to 20 cm of water; expiratory pressure, 4 to 10 cm of water). The primary end point for the comparison between noninvasive ventilation and standard oxygen therapy was death within 7 days after the initiation of treatment, and the primary end point for the comparison between NIPPV and CPAP was death or intubation within 7 days.
RESULTS: A total of 1069 patients (mean [+/-SD] age, 77.7+/-9.7 years; female sex, 56.9%) were assigned to standard oxygen therapy (367 patients), CPAP (346 patients), or NIPPV (356 patients). There was no significant difference in 7-day mortality between patients receiving standard oxygen therapy (9.8%) and those undergoing noninvasive ventilation (9.5%, P=0.87). There was no significant difference in the combined end point of death or intubation within 7 days between the two groups of patients undergoing noninvasive ventilation (11.7% for CPAP and 11.1% for NIPPV, P=0.81). As compared with standard oxygen therapy, noninvasive ventilation was associated with greater mean improvements at 1 hour after the beginning of treatment in patient-reported dyspnea (treatment difference, 0.7 on a visual-analogue scale ranging from 1 to 10; 95% confidence interval [CI], 0.2 to 1.3; P=0.008), heart rate (treatment difference, 4 beats per minute; 95% CI, 1 to 6; P=0.004), acidosis (treatment difference, pH 0.03; 95% CI, 0.02 to 0.04; P<0.001), and hypercapnia (treatment difference, 0.7 kPa [5.2 mm Hg]; 95% CI, 0.4 to 0.9; P<0.001). There were no treatment-related adverse events.
CONCLUSIONS: In patients with acute cardiogenic pulmonary edema, noninvasive ventilation induces a more rapid improvement in respiratory distress and metabolic disturbance than does standard oxygen therapy but has no effect on short-term mortality. (Current Controlled Trials number, ISRCTN07448447.) 2008 Massachusetts Medical Society

Entities:  

Mesh:

Year:  2008        PMID: 18614781     DOI: 10.1056/NEJMoa0707992

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  108 in total

1.  Noninvasive ventilation or continuous positive airway pressure in pulmonary edema patients with respiratory acidosis? Look at the bicarbonates.

Authors:  Stefano Aliberti; Anna Maria Brambilla; Roberto Cosentini
Journal:  Intensive Care Med       Date:  2011-09-27       Impact factor: 17.440

Review 2.  Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Authors:  Kalipso Chalkidou; Tom Walley
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Is the noninvasive ventilatory mode of importance during cardiogenic pulmonary edema?

Authors:  Erwan L'Her
Journal:  Intensive Care Med       Date:  2010-12-07       Impact factor: 17.440

4.  Non-invasive pressure support ventilation and CPAP in cardiogenic pulmonary edema: a multicenter randomized study in the emergency department.

Authors:  Semir Nouira; Riadh Boukef; Wahid Bouida; Wieme Kerkeni; Kaouther Beltaief; Hamdi Boubaker; Latifa Boudhib; Mohamed Habib Grissa; Mohamed Naceur Trimech; Hamadi Boussarsar; Mehdi Methamem; Soudani Marghli; Mondher Ltaief
Journal:  Intensive Care Med       Date:  2010-12-07       Impact factor: 17.440

5.  Lung protective ventilation and hospital survival of cardiac intensive care patients.

Authors:  M Schneck; K Holder; S Gielen; S Nuding; J Schröder; A R Tamm; K Werdan; H Ebelt
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-10-27       Impact factor: 0.840

6.  Acute Heart Failure Treatment.

Authors:  Phillip D Levy; Abdel Bellou
Journal:  Curr Emerg Hosp Med Rep       Date:  2013-06-01

Review 7.  Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure.

Authors:  Bram Rochwerg; Laurent Brochard; Mark W Elliott; Dean Hess; Nicholas S Hill; Stefano Nava; Paolo Navalesi; Massimo Antonelli; Jan Brozek; Giorgio Conti; Miquel Ferrer; Kalpalatha Guntupalli; Samir Jaber; Sean Keenan; Jordi Mancebo; Sangeeta Mehta; Suhail Raoof
Journal:  Eur Respir J       Date:  2017-08-31       Impact factor: 16.671

Review 8.  Ventilatory strategies and supportive care in acute respiratory distress syndrome.

Authors:  Andrew M Luks
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

Review 9.  Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

10.  [Non-invasive ventilation as treatment for acute respiratory insufficiency. Essentials from the new S3 guidelines].

Authors:  B Schönhofer; R Kuhlen; P Neumann; M Westhoff; C Berndt; H Sitter
Journal:  Anaesthesist       Date:  2008-11       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.